You are here: Industry Insights > NICE

News List

NICE rejects NHS funding for Tegsedi, Onpattro pharmatimes
December 13, 2018
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
New NICE standards to improve digital health tech uptake pharmatimes
December 13, 2018
The National Institute for Health and Care Excellence has published new standards setting out the requirements needed to develop digital health technologies for the NHS, to accelerate uptake of products like healthcare apps and wearable devices.
NICE reveals new standards for digital tech pharmaphorum
December 12, 2018
NICE has published new standards setting out the requirements needed to develop digital health technologies for the NHS and speed up uptake of products like healthcare apps and wearable devices.
NICE give go-ahead to Gilead's Yescarta for adults with lymphoma pharmafile
December 10, 2018
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma.
Pharma caps U.K.’s branded-drug spend growth at 2% in exchange for faster drug launches fiercepharma
December 10, 2018
How much are pharma companies willing to pay in exchange for a faster trip to market in the U.K.? As it turns out, a cap of 2% on total branded-drug sales growth should do.
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis pharmaphorum
December 06, 2018
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money.
BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse fiercepharma
December 04, 2018
In September, Britain’s drug-cost watchdog, The National Institute for Health and Care Excellence (NICE), said Bristol-Myers Squibb did not make a convincing enough case that PD-1
NHS funds BMS’ Opdivo to prevent skin cancer returning pharmaphorum
December 03, 2018
NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year to reject the drug in this indication.
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund pharmafile
December 03, 2018
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer Drugs Fund as a treatment option for melanoma, NICE has revealed...
NICE backs use of Bristol-Myers Squibb's Opdivo via Cancer Drugs Fund for completely resected melanoma firstwordpharma
December 02, 2018
The National Institute for Health and Care Excellence issued a final appraisal document on Friday recommending use of Bristol-Myers Squibb's Opdivo (nivolumab) within the Cancer Drugs Fund (CDF) as an option for the adjuvant treatment of completely resect

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page